Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Next Previous
Trial Profile

Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metablok-Arch Biopartners (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Acronyms CS-AKI
  • Sponsors Arch Biopartners

Most Recent Events

  • 22 Apr 2025 According to an Arch Biopartners media release, company that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General Hospital to participate in the Company ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI), the clinical team at Toronto General Hospital (TGH) is now cleared to begin patient recruitment.
  • 08 Jan 2025 According to an Arch Biopartners media release, the clinical teams at Toronto General Hospital and St. Michael's Hospital in Toronto are now seeking final internal approvals and completing final preparations to begin patient recruitment in the first quarter of 2025.The trial continues to recruit patients at the University of Calgary Hospital and five clinical sites in Turkey.
  • 08 Jan 2025 According to an Arch Biopartners media release, the University Health Network Research Ethics Board, through the Clinical Trials Ontario Streamlined Research Ethics Review System, has granted provincial ethics approval for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top